New Delhi, Sept. 3 -- RPG Life Sciences Ltd has agreed to acquire the bulk drugs and intermediates business of Raghava Life Sciences Pvt Ltd, the company said on Thursday.
The Mumbai-listed company, backed by healthcare-focussed private equity firm InvAscent, said the acquisition will be executed through its subsidiary, RPG Active Pharma Ltd, for Rs 135 crore ($14.2 million) on a going-concern basis via a slump sale, according to an exchange filing.
The deal is subject to customary closing conditions and regulatory approvals.
The latest acquisition comes a little over a month after RPG Active Pharma completed the full acquisition of Actis Generics, and InvAscent invested Rs 243.3 crore in the company.
The acquisition is part of RPG Life Sciences' buy-and-build strategy to strengthen its growth platform and create an integrated, scaled API-focussed organisation.
The company expects the deal to expand its manufacturing base, diversify its product portfolio, strengthen regulatory capabilities, and enhance customer access across geographies.
"By combining these manufacturing and product capabilities with Actis' intermediate strengths and RPG Active Pharma's governance, talent and market access, we intend to build a larger presence and capture a greater share of the growing API market," said Ashok Nair, managing director of RPG Life Sciences.
Raghava Life Sciences operates a WHO-GMP- and EU-GMP-approved API manufacturing facility near Hyderabad, spread across around nine acres, with around 300 KL of installed capacity and a dedicated R&D setup.
The company has developed a portfolio of high-growth APls, comprising 22 commercialised products and seven development-stage assets across diabetes, cardiovascular, CNS and other therapeutic segments.
Its active ingredients and intermediates business generated revenue of about Rs 19 crore in FY26. The business includes its manufacturing and R&D facilities, along with a portfolio of 29 API molecules, of which 22 are commercialised and seven are under development.
Published by HT Digital Content Services with permission from VC Circle.